1.Phosphorylation of phospholipase D1 and the modulation of its interaction with RhoA by cAMP-dependent protein kinase.
Min Jung JANG ; Min Jung LEE ; Hae Young PARK ; Yoe Sik BAE ; Do Sik MIN ; Sung Ho RYU ; Jong Young KWAK
Experimental & Molecular Medicine 2004;36(2):172-178
Agents that elevate cellular cAMP are known to inhibit the activation of phospholipase D (PLD). We investigated whether PLD can be phosphorylated by cAMP-dependent protein kinase (PKA) and PKA-mediated phosphorylation affects the interaction between PLD and RhoA, a membrane regulator of PLD. PLD1, but not PLD2 was found to be phosphorylated in vivo by the treatment of dibutyryl cAMP (dbcAMP) and in vitro by PKA. PKA inhibitor (KT5720) abolished the dbcAMP-induced phosphorylation of PLD1, but dibutyryl cGMP (dbcGMP) failed to phosphorylate PLD1. The association between PLD1 and Val14RhoA in an immunoprecipitation assay was abolished by both dbcAMP and dbcGMP. Moreover, RhoA but not PLD1 was dissociated from the membrane to the cytosolic fraction in dbcAMP-treated cells. These results suggest that both PLD1 and RhoA are phosphorylated by PKA and the interaction between PLD1 and RhoA is inhibited by the phosphorylation of RhoA rather than by the phosphorylation of PLD1.
Bucladesine/pharmacology
;
Carbazoles/pharmacology
;
Cell Line, Tumor
;
Cyclic AMP-Dependent Protein Kinases/antagonists & inhibitors/*metabolism
;
Dibutyryl Cyclic GMP/pharmacology
;
Enzyme Inhibitors/pharmacology
;
Humans
;
Indoles/pharmacology
;
Phospholipase D/*metabolism
;
Phosphorylation/drug effects
;
Pyrroles/pharmacology
;
Research Support, Non-U.S. Gov't
;
rhoA GTP-Binding Protein/*metabolism
2.Cinnamyl alcohol attenuates vasoconstriction by activation of K+ channels via NO-cGMP-protein kinase G pathway and inhibition of Rho-kinase.
Yun Hwan KANG ; In Jun YANG ; Kathleen G MORGAN ; Heung Mook SHIN
Experimental & Molecular Medicine 2012;44(12):749-755
Cinnamyl alcohol (CAL) is known as an antipyretic, and a recent study showed its vasodilatory activity without explaining the mechanism. Here we demonstrate the vasodilatory effect and the mechanism of action of CAL in rat thoracic aorta. The change of tension in aortic strips treated with CAL was measured in an organ bath system. In addition, vascular strips or human umbilical vein endothelial cells (HUVECs) were used for biochemical experiments such as Western blot and nitrite and cyclic guanosine monophosphate (cGMP) measurements. CAL attenuated the vasoconstriction of phenylephrine (PE, 1 microM)-precontracted aortic strips in an endothelium-dependent manner. CAL-induced vasorelaxation was inhibited by pretreatment with NG-nitro-L-arginine methyl ester (L-NAME; 10(-4) M), methylene blue (MB; 10(-5) M) and 1 H-[1,2,4]-oxadiazolole-[4,3-a] quinoxalin-10one, (ODQ; 10(-6) or 10(-7) M) in the endothelium-intact aortic strips. Atrial natriuretic peptide (ANP; 10(-8) or 10(-9) M) did not affect the vasodilatory effect of CAL. The phosphorylation of endothelial nitric oxide synthase (eNOS) and generation of nitric oxide (NO) were stimulated by CAL treatment in HUVECs and inhibited by treatment with L-NAME. In addition, cGMP and PKG1 activation in aortic strips treated with CAL were also significantly inhibited by L-NAME. Furthermore, CAL relaxed Rho-kinase activator calpeptin-precontracted aortic strips, and the vasodilatory effect of CAL was inhibited by the ATP-sensitive K+ channel inhibitor glibenclamide (Gli; 10(-5) M) and the voltage-dependent K+ channel inhibitor 4-aminopyridine (4-AP; 2 x 10(-4) M). These results suggest that CAL induces vasorelaxation by activating K+ channels via the NO-cGMP-PKG pathway and the inhibition of Rho-kinase.
Animals
;
Aorta/drug effects/metabolism/physiology
;
Atrial Natriuretic Factor/pharmacology
;
Cyclic GMP/*metabolism
;
Cyclic GMP-Dependent Protein Kinases/*metabolism
;
Dipeptides/pharmacology
;
Human Umbilical Vein Endothelial Cells/drug effects/metabolism
;
Humans
;
Male
;
Methylene Blue/pharmacology
;
NG-Nitroarginine Methyl Ester/pharmacology
;
Nitric Oxide/*metabolism
;
Nitric Oxide Synthase/metabolism
;
Oxadiazoles/pharmacology
;
Phenylephrine/pharmacology
;
Phosphorylation
;
Potassium Channel Blockers/pharmacology
;
Potassium Channels/*agonists
;
Propanols/*pharmacology
;
Quinoxalines/pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Signal Transduction
;
Vasoconstriction/*drug effects
;
Vasodilation/drug effects
;
rho-Associated Kinases/antagonists & inhibitors/*metabolism
3.Role of PKG-L-type calcium channels in the antinociceptive effect of intrathecal sildenafil.
Woong Mo KIM ; Myung Ha YOON ; Jin Hua CUI
Journal of Veterinary Science 2010;11(2):103-106
Sildenafil increases the cyclic guanosine monophosphate (cGMP) by inhibition of a phosphodiesterase 5, thereby leading to an antinociceptive effect. The increased cGMP may exert the effect on an L-type calcium channel through the activation of protein kinase G (PKG). The purpose of this study was to examine the possible involvement of a PKG-L-type calcium channel on the effect of sildenafil at the spinal level. Catheters were inserted into the intrathecal space of male SD rats. Pain was induced by applying 50 microliter of a 5% formalin solution to the hindpaw. The sildenafil-induced effect was examined after an intrathecal pretreatment of a PKG inhibitor (KT 5823), or a L-type calcium channel activator (FPL 64176). Intrathecal sildenafil produced an antinociceptive effect during phase 1 (0~10 min interval) and phase 2 (10~60 min interval) in the formalin test. Intrathecal KT 5823 and FPL 64176 attenuated the antinociceptive effect of sildenafil during both phases. Sildenafil is effective against both acute pain and the facilitated pain state at the spinal level. In addition, the inhibition of an L-type calcium channel by activation of the PKG may contribute to the antinocieptive mechanism of sildenafil in the spinal cord.
Animals
;
Calcium Channel Agonists/pharmacology
;
Calcium Channels, L-Type/*physiology
;
Carbazoles/pharmacology
;
Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors/*physiology
;
Dose-Response Relationship, Drug
;
Male
;
Pain/drug therapy/*physiopathology
;
Pain Measurement
;
Piperazines/*pharmacology/therapeutic use
;
Protein Kinase Inhibitors/pharmacology
;
Purines/pharmacology/therapeutic use
;
Pyrroles/pharmacology
;
Rats
;
Rats, Sprague-Dawley
;
Sulfones/*pharmacology/therapeutic use
4.Dendroaspis natriuretic peptide regulates the cardiac L-type Ca2+ channel activity by the phosphorylation of alpha1c proteins.
Seon Ah PARK ; Tae Geun KIM ; Myung Kwan HAN ; Ki Chan HA ; Sung Zoo KIM ; Yong Geun KWAK
Experimental & Molecular Medicine 2012;44(6):363-368
Dendroaspis natriuretic peptide (DNP), a new member of the natriuretic peptide family, is structurally similar to atrial, brain, and C-type natriuretic peptides. However, the effects of DNP on the cardiac function are poorly defined. In the present study, we examined the effect of DNP on the cardiac L-type Ca2+ channels in rabbit ventricular myocytes. DNP inhibited the L-type Ca2+ current (ICa,L) in a concentration dependent manner with a IC50 of 25.5 nM, which was blocked by an inhibitor of protein kinase G (PKG), KT5823 (1 microM). DNP did not affect the voltage dependence of activation and inactivation of ICa,L. The alpha1c subunit of cardiac L-type Ca2+ channel proteins was phosphorylated by the treatment of DNP (1 microM), which was completely blocked by KT5823 (1 microM). Finally, DNP also caused the shortening of action potential duration in rabbit ventricular tissue by 22.3 +/- 4.2% of the control (n = 6), which was completely blocked by KT5823 (1 microM). These results clearly indicate that DNP inhibits the L-type Ca2+ channel activity by phosphorylating the Ca2+ channel protein via PKG activation.
Action Potentials/drug effects
;
Animals
;
Biological Transport/drug effects
;
Calcium/metabolism
;
Calcium Channels, L-Type/*metabolism
;
Carbazoles/pharmacology
;
Cells, Cultured
;
Cyclic GMP-Dependent Protein Kinases/antagonists & inhibitors
;
Elapid Venoms/*metabolism/pharmacology
;
Enzyme Activation
;
Heart
;
Heart Ventricles/drug effects
;
Myocytes, Cardiac/drug effects
;
Patch-Clamp Techniques
;
Peptides/*metabolism/pharmacology
;
Phosphorylation/drug effects
;
Rabbits